February is AMD and Low Vision Awareness Month. There are several modifications patients can make to their lifestyles that may help reduce their risk of AMD.
The Food and Drug Administration (FDA) has approved Tepezza™ (teprotumumab-trbw; Horizon Therapeutics) for the treatment of thyroid eye disease. Tepezza™, a fully human monoclonal antibody, works by binding to insulin-like growth factor 1 receptor and blocking its activation and signaling. The treatment is administered as an intravenous infusion. The approval of Tepezza™ was supported by…
Want to read more?
Please login or register first to view this content.